AEAlina Errerd

Alina Errerd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alina Errerd has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability

    by Louay Bettaieb, Corina Birzoi, Evan Courmont, Alina Errerd, Anna Rita Cantelmo

    Metabolic heterogeneity has emerged as a defining feature of cancer, yet its origins and therapeutic implications are often considered in a cancer cell-centric manner. Here, we summarize evidence that metabolic diversity is instead dynamically co-regulated by cancer cells, stromal and immune compartments, and by the abnormal vasculature within the tumor microenvironment (TME). We discuss how spatial and temporal fluctuations in oxygen and nutrient availability generate distinct metabolic niches that select for phenotypic plasticity and adaptive cell states. Across these niches, cancer cells differentially engage glycolysis, oxidative phosphorylation (OXPHOS), glutamine and lipid metabolism, and stress-response pathways, generating metabolic states associated with proliferation, survival, metastatic capacity, and therapy resistance. Particular attention is given to tumor endothelial cells (TECs), whose metabolic states influence vascular function and nutrient distribution and may thereby contribute to intratumoral metabolic heterogeneity. In parallel, oncogenic mutations, tissue context, and treatment-induced stress remodel pathway usage and foster the emergence of metabolically adaptable, stem-like, and drug-tolerant populations. Thus, cancer metabolic heterogeneity is shaped by cellular and environmental crosstalk rather than as a static consequence of genetic variation alone. This framework has important translational implications: effective metabolic therapies will require context-aware strategies that target specific niche liabilities while accounting for vascular state, immune function, and adaptive rewiring. Defining when and where these metabolic states create selective dependencies will be essential for translating metabolic heterogeneity into therapeutically actionable vulnerabilities.

  • Open Access

    makeTCR: A Modular Platform for Rapid, Flexible, Scalable, Single-Step T Cell Receptor Synthesis

    by M. Hamberger, M-T. Neuhoff, S.V. Pietrantonio, T. Boschert, C. Maldonado Torres, A. Errerd, C. L. Tan, J. M. Lindner, M. Platten, E. W. Green

    Personalised cell therapies utilising T cell receptors (TCRs) show tremendous clinical promise, though TCR synthesis and validation techniques lag behind our ability to sequence TCR repertoires. To address this gap, we developed makeTCR: a flexible modular, scalable TCR cloning system that enables single-step, 100% fidelity assembly of αβ and γδ TCRs into commonly used expression vectors. By implementing cell-free manufacturing, makeTCR enables patient-derived TCRs to be functionally validated within 48 hours. We provide an open-source, easily extensible, web-based graphical platform that integrates existing tools to simplify and standardise the manufacture of TCRs across all scales of synthesis.


  • Open Access

    Integrated single-cell RNA-seq analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition

    by Mathilde Lebas, Giorgia Chinigò, Evan Courmont, Louay Bettaieb, Amani Machmouchi, Jermaine Goveia, Aleksandar Beatovic, Job Van Kerckhove, Cyril Robil, Fabiola Silva Angulo, et al.

    Endothelial cells (ECs) are highly plastic, capable of differentiating into various cell types. Endothelial-to-mesenchymal transition (EndMT) is crucial during embryonic development and contributes substantially to vascular dysfunction in many cardiovascular diseases (CVDs). While targeting EndMT holds therapeutic promise, understanding its mechanisms and modulating its pathways remain challenging. Using single-cell RNA sequencing on three in vitro EndMT models, we identified conserved gene signatures. We validated original regulators in vitro and in vivo during embryonic heart development and peripheral artery disease. EndMT induction led to global expression changes in all EC subtypes rather than in mesenchymal clusters. We identified mitochondrial calcium uptake as a key driver of EndMT; inhibiting mitochondrial calcium uniporter (MCU) prevented EndMT in vitro, and conditional Mcu deletion in ECs blocked mesenchymal activation in a hind limb ischemia model. Tissues from patients with critical limb ischemia with EndMT features exhibited significantly elevated endothelial MCU. These findings highlight MCU as a regulator of EndMT and a potential therapeutic target.